By Therapeutics
- Anti-platelet Agents
- Beta-blockers
- ACE Inhibitors
- ARBs
- Statins
- Calcium Channel Blockers
- Others
By Disease Type
- Coronary Artery Disease
- Carotid Artery Disease
- Peripheral Arterial Disease
- Cerebrovascular Disease
- Renal Artery Stenosis
- Aortic Aneurysm
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size of the Atherosclerotic Cardiovascular Disease industry is USD 150.8 billion in 2023.
Rising prevalence of obesity, hypertension, diabetes, growing geriatric population, sedentary lifestyles, changing treatment patterns.
High cost of therapies, side effects of statins, failure of clinical trials, stringent regulatory policies, limited awareness in developing regions.
The coronary artery disease segment leads the Atherosclerotic Cardiovascular Disease Market owing to its high prevalence and increasing incidence globally.
Amgen, AstraZeneca, Bayer, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Abbott Laboratories, Teva Pharmaceuticals.
The market is expected to grow at a CAGR of 3.8% from USD 150.8 billion in 2023 to USD 195.8 billion in 2030.
Increasing prevalence of risk factors like obesity, diabetes, hypertension, growing geriatric population, sedentary lifestyles, rising healthcare expenditure, and technologically advanced treatment options.